Anticipating Side Effects From Targeted Therapies in Clinical Trials
Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.
Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.
In phase I, first-in-human studies, side effects are difficult to anticipate. As an example, Dy cites a preclinical trial looking at SMAC-mimetic birinapant, which found that patients may be at risk for hypotension and cardiovascular side effects. Protocols were put in place in early phase trials to monitor patients' blood pressure for six hours, but found that patients did not experience cardiovascular side effects.
Clinical Pearls
Dy also says that when MEK inhibitors were first being developed, it was not anticipated that ocular side effects were a target effect. As researchers recognized this though, Dy says, protocol has been put in place to require baseline ophthalmologic exams for new generation MEK inhibitors.
- Side effects from targeted therapies are difficult to anticipate in first-in-human studies
- When MEK inhibitors were first being developed, it was not anticipated that ocular side effects were a target effect
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
